Viridian Therapeutics Inc Cash Flow Conversion Efficiency
Viridian Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Viridian Therapeutics Inc (VRDN) has a cash flow conversion efficiency ratio of -0.188x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-119.65 Million) by net assets ($636.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Viridian Therapeutics Inc (2012–2025)
Cash flow conversion efficiency of Viridian Therapeutics Inc from 2012 to 2025. This chart illustrates how Viridian Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Viridian Therapeutics Inc (VRDN) share price today for real-time trading data and today's change.
Viridian Therapeutics Inc Cash Flow Conversion Ratio Explained
Viridian Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Viridian Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Viridian Therapeutics Inc ranked by their cash flow conversion efficiency. Also see VRDN company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TX Group AG
SW:TXGN
|
0.039x |
|
SALZGITTER UNSP.ADR 1/10
F:SZGA
|
0.053x |
|
OC Oerlikon Corp AG
SW:OERL
|
-0.015x |
|
Trust Alliance Information Development Inc Ltd Shanghai
SHE:300469
|
-0.039x |
|
China Nonferrous Metal Industry’s Foreign Engineering and Construction Co Ltd
SHE:000758
|
-0.124x |
|
Beijing Tricolor Technology Co Ltd
SHG:603516
|
0.023x |
|
Shanghai Jahwa United Co Ltd
SHG:600315
|
0.020x |
|
Mayora Indah Tbk
JK:MYOR
|
0.058x |
Annual Cash Flow Conversion Efficiency for Viridian Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Viridian Therapeutics Inc from 2012 to 2025. Review how much free cash does Viridian Therapeutics Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $722.17 Million | $-276.39 Million | -0.383x | -10.65% |
| 2024-12-31 | $671.64 Million | $-232.32 Million | -0.346x | +16.98% |
| 2023-12-31 | $442.02 Million | $-184.17 Million | -0.417x | -75.41% |
| 2022-12-31 | $395.06 Million | $-93.84 Million | -0.238x | +18.31% |
| 2021-12-31 | $187.72 Million | $-54.58 Million | -0.291x | -17.20% |
| 2020-12-31 | $120.04 Million | $-29.78 Million | -0.248x | +89.16% |
| 2019-12-31 | $15.75 Million | $-36.06 Million | -2.289x | -337.75% |
| 2018-12-31 | $51.34 Million | $-26.84 Million | -0.523x | +28.52% |
| 2017-12-31 | $38.51 Million | $-28.17 Million | -0.731x | -103.30% |
| 2016-12-31 | $-326.00K | $-7.23 Million | 22.181x | +3447.41% |
| 2015-12-31 | $10.41 Million | $-6.90 Million | -0.663x | -79.39% |
| 2014-12-31 | $5.99 Million | $-2.21 Million | -0.369x | +35.90% |
| 2013-12-31 | $2.03 Million | $-1.17 Million | -0.576x | -298.50% |
| 2012-12-31 | $-21.44 Million | $-6.22 Million | 0.290x | -- |
About Viridian Therapeutics Inc
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develo… Read more